Allien Pharmaceuticals
Levosulpiride (75mg) + Esomeprazole (40mg)
Esjole L 75mg/40mg Capsule SR is a prescription medicine used to treat gastroesophageal reflux disease (acid reflux) by relieving symptoms such as heartburn, stomach pain, or irritation.
Capsule SR
Esjole L 75mg/40mg Capsule SR is a prescription medicine used in the treatment of gastroesophageal reflux disease (acid reflux). It works by relieving the symptoms such as heartburn, stomach pain, or irritation. It also neutralizes the acid production in the stomach to prevent discomfort.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush, or break it. Esjole L 75mg/40mg Capsule SR is to be taken empty stomach.
Esjole L 75mg/40mg Capsule SR is a combination of two medicines: Levosulpiride and Esomeprazole.
Do not consume alcohol while taking Esjole L 75mg/40mg Capsule SR as it can increase the risk of stomach damage. Long-term use may cause weak or broken bones. Take adequate intake of dietary calcium and vitamin D or their supplements. Do not take Esjole L 75mg/40mg Capsule SR for longer than prescribed.
Store this medicine in its original container, tightly sealed. Follow the storage instructions provided on the packaging. Do not dispose of medication down drains or into trash; follow local regulations for proper waste management.
Take Esjole L 75mg/40mg Capsule SR exactly as prescribed by your healthcare provider. It's generally recommended to take one capsule daily on an empty stomach.
Patients with known allergy to any ingredient or excipient in this medication should not take Esjole L 75mg/40mg Capsule SR.
Yes, some patients may experience dizziness (feeling faint, weak, unsteady or lightheaded) when taking Esjole L 75mg/40mg Capsule SR. If you experience dizziness, it's advised to rest and resume medication only once your symptoms subside.
Some studies suggest that taking Esjole L 75mg/40mg Capsule SR could be associated with an elevated risk for hip, wrist, or spine fractures due to osteoporosis. The risk was higher among individuals receiving high doses over a prolonged period (more than one year) of therapy.